These areas are basically monopolized by foreign-funded ecological chain companies that have begun to show their prowess

On August 16th, the most expensive A-share (closing price of 493.

What kind of company is Yiqiao Shenzhou? Why is it so popular?

To answer this question, it is necessary to understand the nature of Yiqiao Shenzhou's business and the status quo of its industrial layout

01 Yiqiao Shenzhou to the left

In October 2016, Yiqiao Shenzhou was separated from Shenzhou Cell, responsible for the research and development, production, sales and technical services of biological reagents

One year later, Yiqiao Shenzhou landed on the ChiNext, with a closing market value of 33.

It is understood that the main business of Yiqiao Shenzhou includes recombinant protein, antibody, gene and culture medium and other products, as well as recombinant protein and antibody development and biological analysis and testing services

Recombinant protein is the company's core product, covering more than 6,000 types.

【Protein is the main research target of life science and innovative drug development

[Antibodies are the most widely used reagents in basic life sciences and biopharmaceutical research

According to Frost & Sullivan data, the scale of China's recombinant protein market in 2020 will be about 1 billion yuan, and Yiqiao Shenzhou's revenue will exceed 48 million yuan, with a market share of about 4.

The antibody category is even worse.

There are many types of biological reagents such as recombinant proteins and antibodies, and the degree of standardization of products is low, and there is a big difference between different products

At present, the domestic biological reagent industry is still in the early stages of development and lacks high-quality domestic recombinant protein and antibody products

02 Eco-chain companies that will welcome the tide of development

Due to the late start of innovative drugs, the domestic life science industry chain has been monopolized by foreign capital for many years, especially in the upstream supply chain with a high degree of external dependence, and high-end products are almost dominated by imports

Most domestic life science support companies were established from 2000 to 2010.

The culture medium is an indispensable raw material for the development of biological drugs

For many years, China has relied heavily on imported cell culture media, and domestic culture media have mainly supplied low-end products

Many domestic companies can provide medium and medium supplements and additives for the production of antibodies and vaccines
.
Since the raw materials used in the current culture medium are relatively fixed, the main difference between the products of each company is reflected in the formula
.
Imported culture media are mainly from Thermo Fisher Scientific, Hyclone, Merck; domestically produced companies such as Optima, Jianshun, Kangsheng, and Maibang Biology have a wide distribution
.

As cell gene therapy is about to enter a period of rapid development, some domestic companies have begun to deploy plasmid production
.
Plasmid is one of the important upstream products in cell gene therapy products, which can be directly applied to the human body, such as plasmid DNA vaccines, gene therapy, immune enhancers, CAR-T, and can also be used to genetically engineer cells to produce recombinant proteins And other biomedical products
.

According to the 2019 report of the QYResearch Medical and Health Research Center, the total sales of vector viruses and plasmid DNA in China in 2020 will be about 172 million yuan, of which the total sales of plasmid DNA will be about 40 million yuan
.
GenScript built the first GMP plasmid workshop in China in November 2018 for the production of pre-clinical and clinical phase I-II plasmid samples.
At present, it has provided IND declaration-level GMP plasmid development and production for many pharmaceutical/CAR-T companies.
Service
.
The lentiviral vector produced by Jinwei Biotech's GMP workshop in Zhangjiang can be used in vivo and in vitro
.

In addition to upstream processes such as plasmids and culture media, companies in the downstream process industry chain of biopharmaceuticals have already taken a place
.
Chromatographic packing is an indispensable consumable in biopharmaceuticals, and is usually used for the separation and purification of biopharmaceuticals
.
For a long time, domestic chromatographic packing materials have basically relied on imports.
The main importers include Cytiva, Thermo Fisher, and Merck
.
Due to the brand barriers of overseas products, it is difficult for domestic products to break through
.
For example, when Nanomicro Technology’s chromatographic packing/chromatographic medium enters the supply chain of downstream biomedical customers, it generally needs to pass the customer’s internal certification.
Different new products sold by different customers need to be certified separately.
The certification time period is between half a year and It varies from 3 years
.
At present, Nanomicro Technology has been certified by many pharmaceutical companies such as Hengrui Pharmaceutical, Fosun Pharmaceutical, Livzon Pharmaceutical, and Dongyang Sunshine
.

Similar to chromatographic fillers, most companies use imported pharmaceutical analysis instruments, such as commonly used microplate readers, mass spectrometers, and nuclear magnetic resonance instruments, in the process of drug development
.
The research and development of new drugs requires high precision of these analytical equipment, but domestic equipment lacks technology and has a low market share
.

On the whole, the above-mentioned products have a common feature: the neck is stuck
.
There are still many unresolved underlying technologies that are really stuck, whether it is key reagent consumables in biopharmaceuticals, or core equipment for large-scale manufacturing, core algorithms for real-world research, and blockchain technology to support global supply chains in the future.
A lot of investment is needed to make a breakthrough
.

Therefore, at this stage, the extensive and urgent demand for import substitution will enable industry chain companies with certain technical barriers and a certain market share to obtain higher premiums and stand out
.